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Abstract
Several bacteria in the gut microbiota have been shown to be associated with inflammatory
bowel disease (IBD), and dozens of IBD genetic variants have been identified in genome-
wide association studies. However, the role of the microbiota in the etiology of IBD in terms of
host genetic susceptibility remains unclear. Here, we studied the association between four
major genetic variants associated with an increased risk of IBD and bacterial taxa in up to 633
IBD cases. We performed systematic screening for associations, identifying and replicating
associations between NOD2 variants and two taxa: the Roseburia genus and the Faecalibac-
terium prausnitzii species. By exploring the overall association patterns between genes and
bacteria, we found that IBD risk alleles were significantly enriched for associations concordant
with bacteria-IBD associations. To understand the significance of this pattern in terms of the
study design and known effects from the literature, we used counterfactual principles to
assess the fitness of a few parsimonious gene-bacteria-IBD causal models. Our analyses
showed evidence that the disease risk of these genetic variants were likely to be partially
mediated by the microbiome. We confirmed these results in extensive simulation studies and
sensitivity analyses using the association between NOD2 and F. prausnitzii as a case study.
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Author summary
In this study, we used observational data to explore associations between host genetics
and the commensal microbiome in inflammatory bowel disease cases. Our analysis identi-
fied four associations involving two genes and four bacterial taxa and replicated two of
these associations in independent cohorts. Then, we developed a counterfactual frame-
work to assess the fitness of a few parsimonious gene-bacteria-IBD causal models. These
analyses confirmed the robustness of the identified associations and highlighted micro-
biota mediation as a potential mechanism underlying the association between IBD and
those genetic variants while ruling out reverse causation and arguing against a bacteria-
IBD association resulting from a shared genetic effect.
Introduction
Most genetic analyses and twin studies published to date support a genetic component of
inflammatory bowel disease (IBD) phenotypes [1]. Recent works showed an estimated herita-
bility on the liability scale of approximately 70–80% for Crohn’s disease (CD) and 60–70% for
ulcerative colitis (UC) [2]. Genome-wide association studies (GWASs) have identified more
than 200 loci associated with IBD, most of which are shared between UC and CD [3–5]. Identi-
fication of these loci has enhanced our understanding of the pathogenesis of IBD, provided
perspective on key pathways, and highlighted an essential role for host defense against infec-
tion. In parallel, recent work noted a potential role of the intestinal microbiota in initiating,
maintaining, and determining IBD-related phenotypes [6–8]. Although generally the com-
mensal microbiota is accepted to induce inappropriate activation of intestinal mucosal immu-
nity, the precise role of the microbiota in the etiology of IBD in terms of host genetic
susceptibility remains unclear.
Both functional and observational studies have been performed in an expanding effort to
address the question of interplay between human genetic variation and the gut microbiome. In
a recent work in mice, we showed that the IBD-associated gene CARD9 affected the composi-
tion and function of the gut microbiota by altering the production of microbial metabolites
and increasing the risk of intestinal inflammation [9]. Similarly, another study explored poten-
tial gene-microbiota interactions in the pathogenesis of IBD [10]. The study showed that the
IBD-associated genes ATG16L1 and NOD2 most likely played an essential role in the beneficial
immunomodulatory properties of Bacteroides fragilis, which protects mice from experimental
colitis. A number of systematic screenings with observational data from healthy human sub-
jects have also been performed using various strategies. In particular, three groups performed
population-based GWASs of 1,561, 1,514 and 1,812 individuals [11–13]. Overall, these studies
confirmed an association between host genetics and the human gut microbiome composition.
Comparison of results between studies also highlighted a probable complex genetic architec-
ture underlying microbiome traits, with little overlap among the detected loci between studies
[14]. Alternatively, at least one GWAS performed with 474 IBD cases identified an association
between NOD2 variants and the relative abundance of Enterobacteriaceae [15].
Altogether, these studies have improved our understanding of the relationship between
host genetics and the human microbiome. However, functional studies and most in vitro
experiments may fail to replicate the precise conditions of the organism under study [16].
Moreover, many species are difficult to grow in vitro, although progress has been made
recently [17, 18]. On the other hand, existing observational studies have focused only on
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association testing and have neither leveraged the multidimensional aspect of the data nor
accounted for the study design to assess causal relationships. Here, we aimed to assess whether
single nucleotide polymorphisms (SNPs) from four major genes (NOD2, CARD9, LRRK2, and
ATG16L1) associated with IBD were also associated with bacterial populations from the gut
and to evaluate the relevance of the underlying causal models. We used a discovery dataset
including 182 IBD cases with both microbiome and host genetic data as well as replication
data from 451 additional IBD cases. First, we applied CMS, a novel association mapping
approach we recently developed to screen for gene-bacteria associations [19]. Then, we devel-
oped an inference framework based on the counterfactual principle [20] to assess the fitness of
a few parsimonious gene-bacteria-IBD models with the observed associations.
Results
SNP-bacteria association screening
Our discovery dataset included variants from four genes (NOD2, CARD9, LRRK2, and
ATG16L1, S1 Table) and bacterial levels from the gut obtained through 16S sequencing of 182
well-phenotyped IBD cases (Table 1). After stringent quality control (S1 Text, S1 Fig), 168
bacterial taxa remained for association testing. The relative proportion of these 168 taxa within
each level is summarized in Fig 1A. A total of 6, 12, 17, 36, 63, and 34 taxa were included in
each of the 6 hierarchical levels (phylum, class, order, family, genus and species, respectively).
The bacterial microbiota was dominated by bacteria from the Firmicutes, Bacteroidetes and
Proteobacteria phyla. When compared to a similar cohort of 38 healthy controls (who had
complete microbiome data but no SNP data) using standard logistic regression (S2 Fig), we
found that 73% of those bacteria displayed a negative association with IBD (Fig 1B).
We performed systematic screening for associations between the four IBD-susceptibility
genetic variants and bacterial quantification. Due to substantial correlation across hierarchical
levels (S3 Fig), we conducted analyses within each level and applied Bonferroni correction to
the p-value within each level to select the best candidate associations. An association test was
performed using standard linear regression after adjusting for established confounding factors
as well as covariates selected by the recently developed CMS approach [19] to increase the sta-
tistical power (S1 Text). We identified seven candidate associations (S2 Table), six of which
involved NOD2 (with c_Bacteroidia, f_Bacteroidaceae, g_Bacteroides, g_Roseburia, R. faecis,
and F. prausnitzii) and one that involved CARD9 (with p_Firmicutes). However, these associa-
tions corresponded to four independent signals (Table 1) with the same association being
Table 1. Sample characteristics.
Female Male Total
CD UC CD UC
N 67 38 48 29 182
Flare (%) 40.3% 55.3% 50.0% 41.4% 46.2%
Mean age 40.3 38.4 39.9 45.5 40.6
Smoking (%) 25.4% 7.9% 31.3% 13.8% 21.4%
Treatment
Oral 5-ASA (%) 20.9% 55.3% 35.4% 62.1% 38.5%
Corticosteroids (%) 11.9% 23.7% 16.7% 31.0% 18.7%
Anti-TNF (%) 56.7% 44.7% 54.2% 31.0% 49.5%
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projected along branches of the phylogenic tree (see S4–S7 Figs for hierarchical plots of the
associations). Indeed, g_Roseburia and R. faecis, which were found to be associated with
NOD2, had a correlation of 0.84 in our dataset. Similarly, f_Bacteroidaceae and g_Bacteroides,
Fig 1. Overview of the bacterial taxa distribution in IBD cases and NOD2 association. Panel a) shows the relative proportion of the 168 bacterial taxa
analyzed across the six hierarchical levels. Only taxa representing more than 0.5% of the total bacterial loading are labelled. Grey areas correspond to unknown,
unmeasured, or underrepresented taxa. Panel b) show the log of the odds ratio (OR) of the labelled bacteria on IBD case-control status and corresponding 95%
confidence interval, as derived using standard logistic regression while adjusting for confounding factors.
https://doi.org/10.1371/journal.pgen.1008018.g001
Fprau & Nod2
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008018 March 8, 2019 4 / 25
which were also associated with NOD2, were almost identical and had a correlation of 0.93
with c_Bacteroidia. The two remaining associations were observed between NOD2 and F.
prausnitzii and between CARD9 and p_Firmicutes. All four signals showed that the IBD risk
alleles (of either NOD2 or CARD9) were negatively associated with the bacteria in question.
To validate these associations, we performed in silico replication using three independent
datasets of adult human subjects with IBD including a total of 451 individuals [15, 21]. Genetic
variant and bacteria data were only partly available in these datasets. CARD9 was available in
only one of the three replication cohorts, and we used the genus g_Faecalibacterium as a proxy
for F. prausnitzii in all three replication analyses. We preprocessed and analyzed the data simi-
larly to that of the discovery sample and combined the two stages using a standard inverse-var-
iance meta-analysis (Table 1). The replication analysis confirmed the associations between the
NOD2 risk allele and decreased abundance of g_Roseburia and F. prausnitzii (Fig 2A); and
both signals passed a stringent Bonferroni correction accounting for all tests performed at the
meta-analysis stage (P< 7x10-5). Firmicutes-CARD9 and Bacteroides-NOD2 replication
showed a signal concordant with those observed during discovery (i.e., a negative association)
but were not significant, indicating either a false positive in the discovery or a lack of statistical
power in the replication. To explore further potential heterogeneity of the SNP effects, we con-
ducted association analyses for the following disease subtypes: CD overall, Ileal CD, non-ileal
CD, and ulcerative colitis (Table 1). The effect estimates for CD and ileal CD were consistent
with the signal observed for IBD during both discovery and replication. Conversely, we
observed heterogeneity of effects for both non-ileal CD and UC. Finally, we confirm further
the NOD2 and F. prausnitzii association, which is a bacterium of particular interest for our
group[22], using real-time quantitative PCR [23] in the discovery samples (Fig 2B).
Model fit while accounting for selection bias
The associations between the IBD risk variants and two bacteria that are also associated with
the IBD risk raise questions about potential reverse causation or conversely potential
Fig 2. Summary of association signals between NOD2 variants and F. prausnitzii. Panel a) presents the boxplots of rank-based inverse normalized F.
prausnitzii from fecal microbiota in the discovery samples and the three replication datasets for non-carrier and carriers of NOD2 risk alleles. Panel b) presents
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mediation of the genetic risk through bacteria. In an attempt to address the question of causal-
ity, we performed a series of analyses to assess the fitness of models matching existing knowl-
edge, which can be summarized as follows. First, the effects of both NOD2 and CARD9 on IBD
are well established [3]. Second, SNPs can only be explanatory variables, which implies a
(direct or indirect) unidirectional relationship. Third, the four taxa from Table 1 (Roseburia
genus, Bacteroidia class, F. prausnitzii, and Firmicutes phylum) have been consistently found
to be negatively correlated with the IBD case status [8, 24]; however, the directionality of the
effect remains a topic of investigation [25]. In regards of these three constraints, four (poten-
tially overlapping) parsimonious underlying causal models can fit the data (Fig 3A–3D): (a)
the effect of the risk allele is mediated by bacterial level; (b) the genetic variant influences both
the disease and the bacteria, inducing a correlation between the two latter variables; (c) the risk
allele and bacteria are independent risk factors of IBD; and (d) IBD mediates the effect of the
risk allele on bacterial level (a so-called reverse causation). Note that these models remain rele-
vant when adding intermediate factors. For example, NOD2 variants have been shown to cor-
relate with lower concentrations of defensins [26], which in turn can be responsible for
Fig 3. Hypothetical causal models. Expected correlation between an IBD risk variant g and a bacteria B negatively correlated with IBD, across four potential underlying
models. For illustrative purposes, g and B are assumed to be continuous and normally distributed and all effects are larger than those observed in real data. Top panels
(a, b, c, and d) present the hypothetical causal diagrams and bottom panels (e, f, g, and h) present the corresponding scatterplots of B as a function of g in the population
(dark grey points, and trend in black), and in cases only (light grey points and trend in red). In model a) the effect of g on IBD is mediated by B; in cases the effect of g on
B is underestimated because of the oversampling of participants carrying risk alleles (e). In model b) the genetic variant influences both IBD and B, inducing a
correlation between IBD and B which is observed in both the whole sample and cases only (f). In model c), g and B act independently on IBD and are therefore not
associated in the population, however g and B are positively correlated in case-only samples because of biased selection (g). Finally, in model d) the effect of g on B is
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changes in the microbiota composition. Alternatively, IBD may be associated with increased
epithelial oxygenation [27], which itself can be responsible for changes in the microbiota com-
position. Such scenarios will be in full agreement with model a) and model d), respectively,
and therefore will not alter the conclusion of the analysis.
Importantly, secondary phenotype analysis in highly ascertained samples (such as in the
present study which includes IBD cases only) can introduce selection bias [28, 29], although
previous work has shown that this bias will be minimal for rare diseases (i.e., those with a
prevalence� 1%, such as IBD [30]) and for cases with low to moderate associations between
variables [29] (S3 Table). To assess the fitness of the data with the four causal models while
accounting for selection bias, we derived an estimator of Δ, the bias induced by the IBD case-
only sampling in the regression coefficient between the risk allele tested and the bacteria. As
shown in S1 Text, Δ can be approximated in some specific situations (common diseases and
modest effects of the predictors), but estimation in more general cases is extremely challeng-
ing. Nevertheless, this theoretical framework allowed us to determine the expected sign of the
risk allele-bacteria association across the scenarios considered without relying on assumption
on the data distributions. Following the counterfactual principle [20], we leveraged this prop-
erty to infer which model had the highest fit for the data based on the signs of the observed
associations. As illustrated in the toy example from Fig 3E–3H, our analytical derivation (see
Materials and Methods) showed that the ascertainment could induce a positive bias of the
SNP-bacteria association in model (c) and lead to the removal of the SNP-bacteria association
in model (d). The results from this analysis are twofold. First, it shows strong evidence that
among the four causal models considered, models (a) and (b), which included a true gene-bac-
teria effect, were the only models in which we expected a persistent negative SNP-bacteria
effect, which was in agreement with the results from Table 1. Second, it rules out selection bias
as a likely explanation for the observed association.
We then asked whether the proposed approximation of Δ could be also informative for the
remaining gene-bacteria association results. Indeed, besides the main signals from Table 1,
our data showed both enrichment for a negative bacterium-disease association (Fig 1B) and
significant enrichment for negative effects of IBD risk alleles on all bacteria levels, with 65%,
71%, 70%, and 60% of the associations negative for ATG16L1, CARD9, LRRK2, and NOD2,
respectively (Fig 4A–4D, p-values for enrichment equal 7.1x10-5, 3.3x10-8, 1.3x10-8, and
5.3x10-3, respectively). After aligning the bacterium-disease and bacterium-SNP associations,
we observed a strong and significant (P = 5.0x10-8) concordance of effects (i.e., most bacteria
showed an association with SNPs and IBD with the same sign) (Fig 4E and 4F). However, our
derivation and simulation study (S1 Text and S8–S12 Figs) demonstrated that, regardless of
the error distribution of the bacterial level, the correlation between the bacterium-disease and
the bacterium-SNP effect estimates in the case-only samples, is expected to be negative under
model c), and null under model d). Therefore, the observed positive correlation (Fig 4F) pro-
vides further evidence against model c) (the risk allele and bacteria act independently on IBD)
and d) (IBD mediates the effect of the risk allele on the bacteria) as generative models, and
again indicates that models a) and b) are the best fits for our data.
Fully deciphering models a) and b) would be extremely challenging because of the complex
interrelationships between the variables in question and the untestable assumptions that
would have to be assumed. However, we found some indications supporting model a) against
model b) in our data. In particular, as illustrated in Fig 3, the association effect estimates
between a genetic variant and bacteria are expected to be slightly deflated in the cases alone
compared to that of the estimates derived in a population including controls in model a) but
should remain unchanged in model b). To assess the fitness of the two models, we use the spe-
cial case of NOD2, which is associated almost exclusively with CD [3]; thus, the NOD2-bacteria
Fprau & Nod2
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associations are expected to be unchanged between all IBD samples (including UC cases) and
CD alone under model b) but should be different in model a). As shown in S13 Fig for all bac-
teria, we found that the effect estimates derived for the CD cases alone were significantly
(P = 5x10-3) smaller than those derived for the complete dataset, which matched the expected
deflation observed in the presence of mediation and therefore provided an argument in favor
of model a).
Sensitivity analyses
As most causal inference approaches, the proposed counterfactual strategy we used in this
study has some limitations. In order to assess the validity of our simulation framework, we per-
formed a series of sensitivity analyses that closely mimicked current knowledge on IBD associ-
ations. First, empirical bacterial levels follow a non-negative, overdispersed distribution and
often harbor a large number of zero values; therefore, use of the Poisson distribution, negative
Fig 4. Correlation between SNP-taxa and IBD-taxa effect estimates. The 168 bacterial taxa were tested for association with the variants from each of the four
genes considered: (a) ATG16L1 (rs12994997), (b) CARD9 (rs10781499), (c) LRRK2 (rs11564258), and (d) NOD2 (rs2066844, rs2066845, and rs2066847). The
histograms on the left panel show the distribution of IBD risk alleles-bacteria association (i.e. of β^ g, the regression coefficients) and the enrichment for negative
effects (in blue, p-values equal 7.1x10-5, 3.3x10-8, 1.3x10-8, and 5.3x10-3, respectively). Panel (e) shows a similar histogram while merging the per-risk allele
change in bacteria level of the four genes (i.e. summing for each bacteria the β^ g of the four genes). Panel (f) shows the distribution of bacteria-IBD association
derived in a IBD cases-controls dataset (β^ B) for each bin from panel (e). Together, panels (e) and (f) show the strong concordance of the gene-bacteria and
bacteria-IBD effects, in agreement with a mediation effect of the risk allele on IBD through the microbiome. In particular, bacteria displaying lower level in
carrier of IBD risk alleles are more likely to be negatively associated with the risk of IBD.
https://doi.org/10.1371/journal.pgen.1008018.g004
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binomial distributions, or hurdle models has been suggested for analyses of microbiome data
[31]. Moreover, we applied a rank-based inverse-normal transformation in our real data analy-
sis, although sparsity remained (after QC, the bacteria had a minimum of 20% nonzero values).
To assess the impacts of these parameters, we performed a simulation study in which the bac-
terial levels were drawn from a negative binomial distribution with varying percentages of
zero-values [0%; 95%]. For each replicate, the SNP-bacteria effect was estimated similar to the
procedure used in the real data analysis. As shown in S14 Fig, no qualitative difference was
found between the untransformed and transformed analyses over the four scenarios consid-
ered (i.e., Fig 3A–3D). Overall, both the true effect (models (a) and (b)) and bias (model (c))
decreased toward the null with the increased data sparsity.
Another potential limitation of our inference was that we assumed that all effects were
homogeneous, and Crohn’s disease and ulcerative colitis cases were treated as a single outcome
variable (IBD). However, as aforementioned, NOD2 variants and F. prausnitzii are mostly
associated with CD, and ileal CD in particular, but show little evidence of an association with
UC [3]. Such effect heterogeneity can be treated as a misclassification problem (i.e., UC cases
are misclassified as CD cases). To assess the impact of genetic heterogeneity, we performed a
second simulation in which the SNP-disease and bacteria-disease associations were present
only for a subset of the cases (thus mimicking UC-CD heterogeneity). In this simulation, all
parameters were set to ensure that the magnitudes of the known effects were similar to those
reported in the literature for the NOD2-F. prausnitzii example and in our analysis. As
described above, we considered the four causal models from Fig 3 and estimated for each repli-
cate and each disease subtype strata the association between the genotype and the bacteria. As
shown in S15 Fig, in this scenario, some of the bias from models (c) and (d) illustrated in Fig
3G and 3H decreased toward the null. Moreover, our simulations showed that under models
(c) and (d), we expected no association signal from either the disease subtype strata or the
whole IBD-cases sample. Again, only models a) and b) fit the observed results from both
Table 1 and Fig 4.
Finally, the validity of some of our analyses relies on the assumption that no intermediate
variable buffers the associations with IBD. For example, genetic variants and bacteria may be
associated with IBD through the disease severity instead of the disease itself. In S16 Fig, we
repeat the simulation from Fig 3 after replacing IBD with the disease severity drawn from a
binomial distribution with n = 5. When assessing the relationships among IBD (here defined
as severity� 1), bacteria and genetic variants, we observed the same qualitative results for
models a), b), and c) as those from our primary example. However, in model d), substantial
correlation between genetics and bacteria persisted in the case sample. Nevertheless, if the
severity is measured, a naïve but efficient solution consists of adjusting for that variable. To the
best of our knowledge, no standard severity score is available for IBD. However, severity is
commonly quantified by ineffective treatment, remission, or the number and location of
inflamed sites. However, only the flare/remission status was available in our study. To assess
potential confounding, we also reran the SNP-bacteria and bacteria-IBD associations. As
shown in S17 Fig, we did not observe any qualitative change in the association pattern.
Discussion
In this study, we explored the effect of four major genes associated with an increased risk of
IBD on bacterial populations from the gut. First, we identified and replicated in independent
cohorts the associations between NOD2 risk alleles and a decrease of both F. prausnitzii and
g_Roseburia. Using a counterfactual framework, we provide further evidence of the robustness
of these associations and highlight potential mediation of the increased risk of IBD due to
Fprau & Nod2
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those genes by the gut microbiome. Importantly, our framework only compares a set of parsi-
monious models and thus provides only probable causes for the observed effects. Moreover,
potential mediation effects do not rule out the presence of other mechanisms through other
pathways acting in parallel. Nevertheless, the extensive sensitivity analyses, which simulated
data in which the bacterial data distributions were overdispersed and sparse, and genetic effect
was heterogeneous, confirmed our results. Our inference is also in agreement with previous
functional studies showing that numerous IBD susceptibility genes are involved in the
response to microorganisms [3], suggesting that the functional consequences of their alter-
ations may be directed toward the gut microbiota. Indeed, studies in mice showed that defects
in innate immunity genes, such as NOD2 or CARD9, impacted the microbiota composition [9,
32, 33]. Moreover, the gut microbiota of NOD2-/- and CARD9-/- mice has pro-inflammatory
effects by itself, because it worsens the colitis severity when transferred to germ-free wild type
mice [9, 34]. Previous work also noted an essential role for NOD2 in the temporal development
and composition of the host microbiota in mice [35]. In human patients with IBD, a significant
association between the NOD2 risk allele and the fecal abundance of Enterobacteriaceae has
been shown[15]. Finally, in another study, homozygocy for the ATG16L1 risk allele was associ-
ated with increased numbers of Fusobacteriaceae in the inflamed ileal mucosa of CD patients
[36]. Building on these previous reports, our study addresses an important missing piece by
describing the role of likely interactions between human genetic variants and the gut micro-
biota in IBD pathogenesis.
Although our study provides evidence against some generative models, including reverse
causation by which the IBD status itself influences the microbiome composition, we fully
acknowledge that strong statements about causality are impossible. Instead, we argue that our
analysis may at least provide support for mediation of genetic effects on IBD through the
microbiome for these variants. Whether other IBD variants display similar patterns remains to
be assessed. Moreover, despite extensive sensitivity analyses, other complex mechanisms may
impact the validity of our results. For example, we cannot fully rule out potential confounding
by disease severity. A strong interaction effect between the genetic variants considered and
other IBD risk factors (i.e., where the magnitude or even the direction of the genetic effect
depends on other factors) may also impact our results. The Mendelian randomization (MR)
principle, which is now commonly applied to genome-wide summary statistics data [37–39],
may provide additional support for potential causal models. Importantly, the proposed parsi-
monious models most likely match the first two assumptions of MR [i.e., i) the genetic variant
is independent of typical confounding factors and ii) the genetic variant is associated with the
mediator in question (here the bacterial level)]. However, the third assumption (i.e., absence of
an effect of the genetic variant on the disease conditional on the mediator) potentially is vio-
lated for IBD, which will make MR analyses more challenging. Therefore, the fundamental
question about correlation or causation [40] will require a range of additional analyses to be
fully addressed.
Using IBD-case samples to explore gene-bacteria associations has some advantages over
other study designs. Studies of healthy subjects can only be used to test for associations
between genetic variants and bacteria but cannot be used to decipher potential causal models
of diseases. On the other hand, although prospective cohorts in the general population have
the potential to circumvent a number of the statistical artifacts we addressed in our study, they
require an unrealistic sample size when studying relatively rare diseases, such as IBD. Impor-
tantly, case-control data will not solve the selection bias issue. Instead, we suggest that future
studies may optimize other components of the study design, especially reducing heterogeneity
of treatment and heterogeneity of disease status across individuals, and measuring additional
potential risk factors of IBD. Association studies of IBD-associated variants with the
Fprau & Nod2
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008018 March 8, 2019 10 / 25
microbiome of healthy participants may also be of interest. At least one previous study
explored this question but did not report any specific enrichment for association of IBD vari-
ants [12]. Nevertheless, by merging summary statistics from the available NOD2 variants
(rs2066845 and rs2066845) from this study, we observed signals going in the same direction
(g_Roseburia z = -1.11; F. prausnitzii z = -0.79), although neither signal was nominally signifi-
cant (P = 0.27 and P = 0.43, respectively). Finally, we merged all three NOD2 variants into a
binary variable defined as the presence/absence of at least one variant. Although the effect of
each of these variants is established, their combined effect is not well defined [41–43]. Under-
standing the relative contribution of each NOD2 variant to the overall signal we observed is of
primary interest but will again require a larger sample size.
Here, we showed that part of the effect of IBD-risk variants was most likely mediated by an
effect on the bacterial microbiota. The identification of this potential causal pathway from
genetic variants to IBD in observational human data is important for understanding the patho-
genesis of IBD and other microbiota-driven diseases. Moreover, the findings suggest that tar-
geting the microbiota may be an effective therapeutic strategy to overcome gene-induced
disease susceptibility.
Materials and methods
Patients and samples collection
All subjects were recruited in the Gastroenterology Department of the Saint Antoine Hospital
(Paris, France) and provided informed consent, and approval was obtained from the local eth-
ics committee (Comite de Protection des Personnes Ile-de-France IV, IRB 00003835, Suivithe-
que study). Their microbiota composition analysis has been published[44]. A diagnosis of IBD
was defined by clinical, radiological, endoscopic and histological criteria. None of the study
participants had taken antibiotics or used colon-cleansing products for at least 2 months prior
to enrolment. Fecal samples were collected from 182 patients with IBD. Whole stools were col-
lected in sterile boxes and immediately homogenized, and 0.2 g aliquots were frozen at −80˚C
for further analysis. Details of the genomic DNA extraction, 16S rRNA gene sequencing, and
additional real-time quantitative PCR are presented in the S1 Text.
16S rRNA gene sequencing
Genomic DNA was extracted from 200 mg of feces as described previously[45]. Following
microbial lysis involving both mechanical and chemical step, nucleic acids were precipitated
by isopropanol for 10 minutes at room temperature, followed by incubation for 15 minutes on
ice, and centrifugation for 30 minutes at 15,000g and 4˚C. Pellets were suspended in 112 μL of
phosphate buffer and 12 μL of potassium acetate. After the RNase treatment and DNA precipi-
tation, nucleic acids were be recovered by centrifugation at 15,000g and 4˚C for 30 minutes.
The DNA pellet were suspended in 100 μL of TE buffer. After extraction, the total DNA con-
centration was measured using PicoGreen (Invitrogen), and global 16S gene DNA copy num-
bers were measured using a qPCR method adapted from Maeda et al[46] allowing for
inhibition effect estimation and DNA concentration adjustment.
The sequence region of the 16S rRNA gene spanning the variable region V3-V5 was ampli-
fied using the broad-range forward primer For16S_519 (CAGCMGCCGCGGTAATAC) and
reverse primer Rev16S_926 (CCGTCAATTCMTTTGAGTTT). Amplification reaction (initial
activation step at 94˚C for 1 min followed by 30 cycles of 94˚C for 15 s, 43˚C for 15 s and 68˚C
for 45 s plus final incubation at 68˚C for 1 min) was performed in a total volume of 100 μL
containing 1X PCR buffer, 2 mM MgSO4, 1 U of DNA High Fidelity Taq Polymerase (Invitro-
gen, Carlsbad, CA), 625 nM of each barcoded primer (IDT), 250 μM of each dNTP
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(Invitrogen) and the concentration-adjusted DNA sample. A bidirectional library was pre-
pared using the One Touch2 Template Kit and sequenced on PGM Ion Torrent using the Ion
PGM Sequencing 400 Kit (Life Technologies, Carlsbad, CA).
The sequences were demultiplexed and quality filtered using the Quantitative Insights Into
Microbial Ecology (QIIME, version 1.8.0) software package. The sequences were trimmed for
barcodes and PCR primers and were binned for a minimal sequence length of 200 pb. The
sequences were then assigned to Operational Taxonomic Units (OTUs) using the UCLUST
algorithm[47] with a 97% threshold pairwise identity and taxonomically classified using the
Greengenes reference database[48]. Rarefaction was performed (10,000 and 2,000 sequences
per sample respectively for discovery and replication cohorts). Rarefied reads counts were then
transpose into per-individual proportion and used to compare OTUs abundances across sam-
ples. We identified a total of 897 bacterial taxa across 6 hierarchical levels (Phylum, Class,
Order, Family, Genus and Species). However 577 taxa were detected in less than 20% of the
participants (S1 Fig), and were therefore removed to limit sparsity issue in further analyses.
Bacterial level pre-processing
Large-scale genomics data (e.g. microarray, proteomic, metabolomic) are commonly pre-pro-
cess, applying various transformation and normalization procedures to remove confounding
effects[49] but also to increase power[50]. Pre-processing can strongly impact both power and
robustness[51] and should therefore be conducted carefully. To our knowledge, there is no
established consensus on how to perform optimal pre-processing of microbiome data. The
hierarchical relationship between taxa (Fig 1), along with strong pairwise correlation within
each level (S3 Fig), makes pre-processing particularly challenging. Moreover, as we recently
showed[52], standard approaches such as adjusting outcomes for the top principal compo-
nents (PCs) of the taxa level (as commonly done in gene expression analysis[53]) can poten-
tially introduce bias in our analysis–a phenomenon that would be amplified in our data
because PCs can capture the shared variability of specific bacterial families. Therefore, we
focused the pre-processing on transformation and filtering that will ensure the validity of the
statistical tests. In particular, linear regression is sensitive to the presence of outliers, assumes a
normal distribution of the outcome residual, and requires sufficient sample size for reliable
effect estimation when multiple predictors are considered. The raw distributions of bacterial
levels show widespread and strong outliers and skewed distribution.
In practice, we first filtered out all elements quantified in <20% of individuals or poorly
annotated. We did not to use a more stringent threshold to allow for a screening as broad as
possible, while we validated the most significant results through replication analysis in inde-
pendent datasets. However, as showed in our sensitivity analyses (S13 Fig) we expect very low
power to identify association with taxa quantified in less than 70% of the individuals in our
dataset. Indeed, all top results from our assocaition analysis (Table 2) involve taxa were pres-
ent in more than 85% of the individuals (e.g. Fprau was quantified in more than 95% of the
individuals). Second, we applied rank-based inverse normal transformation to address both
non-normal distribution of the bacteria levels and avoid false signal due to outliers. We
acknowledge that such non-linear transformation can affect the inference [54]. However,
rank-based inverse normal transformation is very commonly used in marginal genetic effect
analyses of ‘omics data (e.g. microarray, RNA-seq, metabolites, which have properties similar
to our microbiome data) and the current consensus is that, despite drawbacks, it remains a
simple and efficient solution in many settings as compared to more complex approaches [55,
56]. Moreover, we also noted that rank-based inverse normal transformation is also now used
in some microbiome data analysis[11, 57].
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Statistical analysis
We performed a systematic screening for association between the selected genetic variants and
bacterial level. Association test were performed using standard univariate linear regression
including seven potential confounding factors: gender, age, smoking, and treatment for 5-ami-
nosalicylic acid, corticosteroids, anti-TNF agent, thiopurine or methotrexate. Importantly,
we did not adjust the model for disease type (UC versus CD) as we demonstrated in a recent
study that adjusting for variables that have a genetic basis might invalid association test [58].
To increase statistical power we also employed CMS (Covariates for Multiphenotype Studies),
an approach recently developed by our group [19] to select additional covariates from the
available bacterial data. Hence the final test we applied consisted in evaluating b^G, the esti-
mated effect of the genetic variant G on the quantification of a bacteria Y, in the following
model:
Y � b0 þ bGGþ βZZþ βCC
where βZ and βC are vectors of effect of Z, the counfounding factors, and C, a set of bacteria
selected by CMS. To account for the hierarchical structure of the data, CMS search for covari-
ates C of an outcome Y was conducted only within taxa of the same hierarchical levels as Y.
Table 2. Bacteria-genetic variant associations.
Outcome Gene Disease Discovery Replication Meta-analysis
β� (Pval) β� (Pval) β� (Pval)
Firmicutes CARD9 IBD -0.38 (2.3x10-4) -0.08 (0.50) -0.25 (1.1x10-3)
CD -0.43 (7.4x10-4) -0.05 (0.76) -0.30 (2.8x10-3)
CDil -0.44 (2.7x10-3) -0.08 (0.67) -0.31 (6.4x10-3)
CDni -0.46 (0.23) 0.85 (0.041) 0.12 (0.66)
UC -0.25 (0.19) 0.07 (0.74) -0.10 (0.46)
Bacteroides NOD2 IBD -0.62 (1.9x10-4) -0.05 (0.58) -0.20 (0.014)
CD -0.57 (4.1x10-3) -0.17 (0.20) -0.30 (6.3x10-3)
CDil -0.65 (3.3x10-3) -0.16 (0.26) -0.31 (8.7x10-3)
CDni - -0.42 (0.41) -0.42 (0.41)
UC -0.50 (0.18) 0.24 (0.15) 0.11 (0.47)
Roseburia NOD2 IBD -0.58 (6.4x10-5) -0.22 (0.059) -0.36 (4.9x10-5)
CD -0.46 (6.7x10-3) -0.26 (0.076) -0.35 (1.5x10-3)
CDil -0.30 (0.082) -0.34 (0.030) -0.32 (5.2x10-3)
CDni - -0.27 (0.61) -0.27 (0.61)
UC -0.76 (0.0052) 0.14 (0.54) -0.25 (0.14)
F. prausnitzii NOD2 IBD -0.56 (4.0x10-4) -0.30 (0.014) -0.40 (3.2x10-5)
CD -0.48 (6.4x10-3) -0.20 (0.19) -0.32 (4.7x10-3)
CDil -0.51 (0.014) -0.31 (0.050) -0.39 (2.0x10-3)
CDni - -0.08 (0.86) -0.08 (0.86)
UC -0.32 (0.33) -0.14 (0.61) -0.22 (0.31)
Abbreviation: CD, Crohn’s disease; UC, ulcerative colitis; CDil, CD ileal; CDni, CD non-ileal
�
Beta coefficients were derived when using the allele associated with an increased risk of IBD as the coded allele. Outcomes were normalized. All outcomes had a
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Replication study
We performed a replication of our main results using two independent studies. Both studies
are themselves combination of multiple cohorts. The first study included 474 adult IBD cases
from three cohorts. We only considered two of them, MGH (Mass General Hospital, N = 170)
and MSH (Mont Sinai Hospital, N = 65), both from the United States. We discarded the last
one because of missing data on the main confounding factors. In these two cohorts mucosa
associated microbiota was analyzed from intestinal biopsies. Because of major differences in
the composition and treatment between MGH and MSH (S4 Table), we analyzed the two
cohorts separately and refer to them as replication 1 and replication 2. Moreover, all partici-
pants that undergone proctocolectomy with ileoanal anastomosis were excluded a priori, as
the microbiota composition might be dramatically impacted by this operation and therefore
not reflect the overall population. The second study included 216 IBD cases from a Netherland
cohort with almost complete covariates data [21]. We refer to this dataset as replication 3. All
replication analyses (1, 2, and 3) were adjusted for gender, age, smoking, mesalamine, antibiot-
ics, and immunosuppressant treatments. To ensure our discovery signal was not biased
because of the used of covariates identified by the CMS approach, we did not use CMS at the
replication stage. Finally, we performed an inverse-variance meta-analysis of all three replica-
tions dataset using the R metafor package. Study-specific results are presented in S5 Table.
Evaluation of ascertainment bias
The established association between IBD and both the genetic variants and the bacterial levels
implies that the joint distribution of these variables in IBD cases only might not representative
of the overall population. This is a known issue that has been widely discussed in the context
of secondary trait analysis [28, 29, 59–62]. Indeed, with the surge of case-control genome-wide
association study, a number of investigators are facing the problem of analyzing secondary
phenotypes, measured on behalf of the disease status, while accounting for the sample ascer-
tainment. These works show that when mishandled, secondary trait analysis can be biased. In
particular, if a predictor X (here, a genetic variant) and a secondary phenotype Y (here, a bacte-
rial level) are associated with the outcome (here, IBD), the two variables might display a false
association. While studies showed that for rare diseases (i.e. prevalence� 1%, as for IBD), and
small effect, the Y~X association test in disease cases only, as done in this study, is expected to
be small [28]. Estimating the changes in expected effect estimates depending on sampling
design is a non-trivial problem. As discussed in the literature for logistic models [29, 63],it has
a direct relationship with the parametrization of the underlying generating models.
Consider a biallelic genetic variant g, generated from a binomial distribution with minor
allele frequency p, a bacterial level b following a distributionO and a disease status d with prob-
ability π. For mathematical convenience we further consider D, B and G for standardized d, b
and g, respectively. We are interested in estimating Δ = βd = 1−β, the difference between the
regression coefficient between G and B in the general population (β). Without assuming any
particular distribution of the variables, Δ has the general form:








E½BGjd ¼ 1�   E½Bjd ¼ 1�E½Gjd ¼ 1�
s2Gjd¼1
  E BG½ �
where s2Gjd¼1 ¼ varðGjd ¼ 1Þ is the variance of G conditional on d = 1. As E½B� ¼ E½G� ¼
Fprau & Nod2
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008018 March 8, 2019 14 / 25
E½D� ¼ 0, the expectation conditional on d can we be rewritten as:
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Note that the above formulation of Δ is valid for any generating model and data distribution.
Model fit using estimates of selection bias
We are interested in assessing the impact of the bias Δ on the SNP-bacteria association for the
four hypothetical causal models (Fig 3A–3D) in order to determine their fitness to our data.
Here we assumed IBD status follows a binomial distribution with n = 1 and is linked to other
variable through a logistic model, and we constrained the model to fit known associations: the
positive association between the genetic variants and IBD [3, 4], and the negative association
between the four taxa (Roseburia genus, Bacteroidia class, F. prausnitzii, and Firmicutes
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phylum) and IBD [8, 24, 64]. In model a) the effect of g on D is mediated by B. In model b) the
effect of g on B is mediated by D. In model c), g and B act independently on IBD and are not
associated in the population. Finally in model d), B and D are both influenced by U, the
unmeasured risk factors.
The data can be expressed through the following generative models:
Model aÞ :
(B ¼ bGþ εB
E½djB� ¼ 1=½1þ e  ðo0þoBBÞ�
Model bÞ :
(B ¼ bGþ εB
E½djG� ¼ 1=½1þ e  ðo0þoGGÞ�
Model cÞ : fE½djB;G� ¼ 1=½1þ e  ðo0þoBBþoGGÞ�
Model dÞ :
(B ¼ gDþ εB
E½djG� ¼ 1=½1þ e  ðo0þoGGÞ�
Building on our estimator of Δ and leveraging previous work relating logistic and linear model
[63, 65] we further demonstrate that when the disease is common, under the assumption of
normality of B and G and small effects of the independent variables, Δ for the four hypothetical
causal models can be approximated as (S1 Text and S8 Fig):












Dd ¼ E½BG� �   goGsd
However, the normality assumption will not hold in general for both G (being drawn from a
binomial) and B (e.g. drawn from a negative binomial), and the two other hypothesis (common
disease and small effect size) are also violated in our data. Nevertheless, as previously showed
[65], and as confirmed by our simulations (S1 Text and S9–S12 Figs), parameters from the lin-
ear approximation have the proper sign, so that the above Δ approximations is still informative
about the direction of the bias, whatever the residual distribution of B and G. It follows that:
signðDaÞ ¼   signðbÞ
signðDcÞ ¼   signðoGoBÞ
signðDdÞ ¼   signðgoGÞ
Thus, in model a) the effect estimate will be biased toward the null, i.e the magnitude of the
genetic effect on bacteria will be underestimated. In model b), we expect the effect to be the
same in case only sample as in the whole population. In model c), the ascertainment will induce
a bias which direction has opposite sign to the product of the genetic effect on IBD and the
bacterium effect on IBD. Finally In model d), we expect the indirect effect of the genetic variant
on the bacterium to be null in a case only sample.
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S1 Fig. Non-zero abundance of taxa. Density (a) and cumulative distribution (b) of the per-
centage of non-zero abundance for each of 897 bacterial taxa across the 182 IBD cases ana-
lyzed. The red and blue dashed lines in (b) correspond to a non-zero abundance of 95% and
80%, respectively. There was 494 (~55%) and 320 taxa (~36%) with lower values, respectively,
i.e. taxa that are present in more than 5% and 20% of the participants, respectively.
(TIF)
S2 Fig. Overview of the bacterial taxa distribution in IBD controls. Relative proportion of
each of the 168 bacterial taxa analyzed across each of the six hierarchical levels. Only taxa rep-
resenting more than 0.5% of the total bacterial loading are labelled. Grey areas correspond to
unknown, unmeasured, or underrepresented taxa.
(TIF)
S3 Fig. Pairwise correlation between bacterial level. Pairwise Pearson correlation between
bacterial taxa derived across the 182 IBD cases. Taxa were grouped by hierarchical strata (Phy-
lum, Class, Order, Family, Genus and Species), so that the panels from the diagonal represent
the correlation within each stratum, while off-diagonal panels present cross-strata correlation.
Strength of correlation is presented as a gradient from dark blue (-1) to dark red (1).
(TIF)
S4 Fig. Summary of association signals for ATG16L1. Bacterial levels were tested for associa-
tion with SNP rs12994997 from gene ATG16L1. Positive and negative associations are repre-
sented as gradient of orange and blue, respectively. The horizontal axis indicates the
corresponding–log10(p-value). Results are presented across the taxa hierarchy. Empty cells
indicate that the subsequent element is unknown or unmeasured in our samples.
(TIF)
S5 Fig. Summary of association signals for CARD9. Bacterial levels were tested for associa-
tion with SNP rs10781499 from gene CARD9. Positive and negative correlations are repre-
sented as gradient of orange and blue, respectively. The horizontal axis indicates the
corresponding–log10(p-value). Results are presented across the taxa hierarchy. Empty cells
indicate that the subsequent element is unknown or unmeasured in our samples.
(TIF)
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S6 Fig. Summary of association signals for LRRK2. Bacterial levels were tested for associa-
tion with SNP rs11564258 from gene LRRK2. Positive and negative correlations are repre-
sented as gradient of orange and blue, respectively. The horizontal axis indicates the
corresponding–log10(p-value). Results are presented across the taxa hierarchy. Empty cells
indicate that the subsequent element is unknown or unmeasured in our samples.
(TIF)
S7 Fig. Summary of association signals for NOD2. Bacterial levels were tested for association
with the genetic risk score of gene NOD2 (rs2066844 + rs2066845 + rs2066847). Positive and
negative correlations are represented as gradient of orange and blue, respectively. The horizon-
tal axis indicates the corresponding–log10(p-value). Results are presented across the taxa hier-
archy. Empty cells indicate that the subsequent element is unknown or unmeasured in our
samples.
(TIF)
S8 Fig. Linear approximation of logistic model. We simulated four datasets including each
20,000 individuals. For each dataset we draw a genetic variant G from a binomial assuming a
minor allele frequency of 0.1, a bacterial level B while using arbitrarily various distributions,
and a disease status d generated from a logistic model, E½djB;G� ¼ 1=ð1þ e  ½o0þoBBþoGG�Þ.
We then performed linear regression of the disease probability while including an increasing
number of polynomial terms of the predictors B and G and their interactions (model0 to
model3). At the two extremes, model0 includes only the marginal effects of the predictor
(E½djB;G� � l0 þ lGGþ lBB), while model3 include polynomial up to a power of 4 and any
relevant interactions. For each model we plotted the simulated disease probability against the
fitted values for model0 to model3. We use four sets of parameters to illustrate the requirement
for additional terms in the linear model as the prevalence moves away from 0.5 and effect are
getting larger. In (a) we considered a disease prevalence of 0.5, a normally distributed B, and
modest B and G effects. In (b) we slightly increase effects and considered a rare disease case. In
(c) we used generated B from an exponential, consider low disease prevalence and large effects.
Finally, in (d) we considered a rare disease, very large effects and generated B from a uniform
distribution.
(TIF)
S9 Fig. Bias for common disease and large effect. We simulated series of 1,000 replicates
each including 100,000 individuals. For each replicate we draw a genetic variant G, a
bacterial level B, and a disease status d using the two equations B = βG + γD + εB and
E½djB;G� ¼ 1=ð1þ e  ½o0þoBBþoGG�Þ. We use three sets of parameters to match model a (left col-
umn), model b (middle column) and models c and d (right column), while changing the direc-
tion of the effect. In this simulation, all effects (panel a) were assumed to be large and disease
prevalence high (~30%). For each simulation we estimated through standard linear regression
the association coefficient between B and G in the whole population and in the cases only.
Median of the coefficient in the whole population is indicated by a bold red line, while coeffi-
cients observed in cases only are provided in boxplots. The difference between the two coeffi-
cients (case only—whole population), Δ, is indicated in blue if negative and in pink if positive.
For each set of parameters (panel a), we derived the proposed approximation of Δ (panel b),
and the aforementioned estimates while drawing εB from a normal distribution (panel c), an
exponential distribution (panel d), and a uniform distribution (panel e).
(TIF)
S10 Fig. Bias for common disease and moderate effect. We simulated series of 1,000 repli-
cates each including 100,000 individuals. For each replicate we draw a genetic variant G, a
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bacterial level B, and a disease status d using the two equations B = βG + γD + εB and
E½djB;G� ¼ 1=ð1þ e  ½o0þoBBþoGG�Þ. We use three sets of parameters to match model a (left col-
umn), model b (middle column) and models c and d (right column), while changing the direc-
tion of the effect. In this simulation, all effects (panel a) were assumed to be large and disease
prevalence high (~30%). For each simulation we estimated through standard linear regression
the association coefficient between B and G in the whole population and in the cases only.
Median of the coefficient in the whole population is indicated by a bold red line, while coeffi-
cients observed in cases only are provided in boxplots. The difference between the two coeffi-
cients (case only—whole population), Δ, is indicated in blue if negative and in pink if positive.
For each set of parameters (panel a), we derived the proposed approximation of Δ (panel b),
and the aforementioned estimates while drawing εB from a normal distribution (panel c), an
exponential distribution (panel d), and a uniform distribution (panel e).
(TIF)
S11 Fig. Bias for rare disease and large effect. We simulated series of 1,000 replicates each
including 100,000 individuals. For each replicate we draw a genetic variant G, a bacterial level
B, and a disease status d using the two equations B = βG + γD + εB and E½djB;G� ¼
1=ð1þ e  ½o0þoBBþoGG�Þ. We use three sets of parameters to match model a (left column), model
b (middle column) and models c and d (right column), while changing the direction of the
effect. In this simulation, all effects (panel a) were assumed to be large and disease prevalence
high (~30%). For each simulation we estimated through standard linear regression the associa-
tion coefficient between B and G in the whole population and in the cases only. Median of the
coefficient in the whole population is indicated by a bold red line, while coefficients observed
in cases only are provided in boxplots. The difference between the two coefficients (case only
—whole population), Δ, is indicated in blue if negative and in pink if positive. For each set of
parameters (panel a), we derived the proposed approximation of Δ (panel b), and the afore-
mentioned estimates while drawing εB from a normal distribution (panel c), an exponential
distribution (panel d), and a uniform distribution (panel e).
(TIF)
S12 Fig. Bias for rare disease and moderate effect. We simulated series of 1,000 replicates
each including 100,000 individuals. For each replicate we draw a genetic variant G, a bacterial
level B, and a disease status d using the two equations B = βG + γD + εB and E½djB;G� ¼
1=ð1þ e  ½o0þoBBþoGG�Þ. We use three sets of parameters to match model a (left column), model
b (middle column) and models c and d (right column), while changing the direction of the
effect. In this simulation, all effects (panel a) were assumed to be large and disease prevalence
high (~30%). For each simulation we estimated through standard linear regression the associa-
tion coefficient between B and G in the whole population and in the cases only. Median of the
coefficient in the whole population is indicated by a bold red line, while coefficients observed
in cases only are provided in boxplots. The difference between the two coefficients (case only
—whole population), Δ, is indicated in blue if negative and in pink if positive. For each set of
parameters (panel a), we derived the proposed approximation of Δ (panel b), and the afore-
mentioned estimates while drawing εB from a normal distribution (panel c), an exponential
distribution (panel d), and a uniform distribution (panel e).
(TIF)
S13 Fig. NOD2-bacteria association in all IBD cases and CD cases only. We compared effect
estimates for NOD2-bacteria association derived using standard linear regression, after adjust-
ing for confounding factors, in all IBD cases (βIBD) and CD cases only (βCD). The gradient of
colors (pink to red) and size of each point (small to large) indicate increasing significance of
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NOD2-bacteria association in the complete IBD cases dataset. Under the confounding model
(b), where CD-bacteria association is partly confounded by a shared genetic effect of NOD2
on both outcomes, the two estimates have the same expectation and therefore the regression
slope between the two estimates should be equal to 1 (black line). The observed slope (red
line), which equals 0.88, is significantly different from 1 (P = 5e-3, tested using a student t-test
assuming an expected slope equals to 1).
(TIF)
S14 Fig. Impact of data sparsity. We simulated series of 20,000 replicates each including
10,000 individuals. For each individual, we generated a genetic variant, a bacteria and a case-
control status following the four models (a, b, c and d) from Fig 3. The genotype was simulated
using a binomial distribution with frequency of the coded allele randomly drawn in [0.05,
0.95]. The bacterial level was simulated using a negative binomial distribution were the disper-
sion parameters of each replicate were chosen so that the proportion of zero value vary from
0% to 95% across replicates. The case-control status was drawn from a binomial distribution
with probability derived using a logit function with parameters matching the each of the four
models. For each replicate, a subset of 200 cases was randomly chosen and used to test for asso-
ciation between the genotype and the bacteria using standard linear regression. The left (a)
and middle (b) panels show the signed explained variance obtain from this experiment before
and after applying an inverse-rank based normal transformation of the bacterial level, respec-
tively. The red line shows the trend derived using local fitting as implemented in R loess func-
tion with default parameters. The right panels (c) present median p-values from the latter
experiment derived over bins of replicates with a range of percentage of zero-values.
(TIF)
S15 Fig. Impact of effect heterogeneity on bias. We simulated series of 10,000 replicates each
including 30,000 individuals. For each individual, we generated a genetic variant G, a bacteria
B and two case-control status, CD, which was defined based on the four causal models (a, b, c
and d) from Fig 3, and UC, which was drawn independently of other variables. The two dis-
eases were merged to form the IBD status. The genotype was simulated using a binomial distri-
bution with frequency of the risk allele randomly drawn in [0.05, 0.2]. The bacterial level was
simulated using a negative binomial distribution while randomly drawing the dispersion
parameter so that the proportion of zero-value ranges in [0%, 80%]. The case-control status
was drawn from a binomial distribution with probability derived using a logit function. All
parameters from the simulation were set so that it match estimates from the literature and our
primary results. The three lower panels show empirical distribution of those parameters esti-
mated in the whole population. Disease prevalence, genetic effect and bacteria-disease associa-
tion matched both in direction and magnitude for all causal models. We then randomly
sampled from each replicate, a subset of 200 cases tested for association between G and B using
standard linear regression, and after applying an inverse rank-based normal transformation of
B. The test was applied in the sub-sample of IBD cases, but also in the sub-group of CD cases
only and the sub-group of UC cases only.
(TIF)
S16 Fig. Assuming an intermediate variable confounds the effect on IBD. We performed a
simulation similar to Fig 3, expect that we replaced IBD status by a severity score. We plotted
regression slopes between bacteria and the genetic variant in the whole population, and in
cases only, using either the raw bacterial data or after adjusting for severity. Top panels (a, b, c,
and d) present the hypothetical causal diagrams and bottom panels (e, f, g, and h) present the
corresponding scatterplots of B as a function of g in the population (dark grey points, and
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trend in black), in cases only (light grey points and trend in red), and again, in cases only but
after adjusting the bacteria for severity (blue crosses, and trend in dark blue). In model a) the
effect of g on severity is mediated by B; in cases the effect of g on B is underestimated because
of the oversampling of participants carrying risk alleles (e). In model b) the genetic variant
influences both severity and B, inducing a correlation between severity and B which is
observed in both the whole sample and cases only (f). In model c), g and B act independently
on severity and are therefore not associated in the population, however g and B are positively
correlated in case-only samples because of biased selection (g). Finally, in model d) the effect
of g on B is mediated by severity; the indirect association between g and B observed in the gen-
eral population is still present in cases only, but is canceled when adjusting bacteria for severity
(h).
(TIF)
S17 Fig. Sensitivity analysis adjusting for flare-remission. We performed the same analysis
as for Fig 4, expect that we adjusted all analyses for flare-remission. The 168 bacterial taxa were
tested for association with the variants from each of the four genes considered: (a) ATG16L1
(rs12994997), (b) CARD9 (rs10781499), (c) LRRK2 (rs11564258), and (d) NOD2 (rs2066844,
rs2066845, and rs2066847). The histograms on the left panel show the distribution of IBD risk
alleles-bacteria association (i.e. of b^g , the regression coefficients) and the enrichment for nega-
tive effects (in blue, p-values equal 0.018, 1.3x10-8, 9.3x10-6, 0.018, respectively). Panel (e)
shows a similar histogram while merging the per-risk allele change in bacteria level of the four
genes (i.e. summing for each bacteria the b^g of the four genes). Panel (f) shows the distribution
of bacteria-IBD association derived in an IBD cases-controls dataset (b^B) for each bin from
panel (e). Together, panels (e) and (f) show the strong concordance of the gene-bacteria and
bacteria-IBD effects, in agreement with a mediation effect of the risk allele on IBD through the
microbiome. In particular, bacteria displaying lower level in carrier of IBD risk alleles are
more likely to be negatively associated with the risk of IBD.
(TIF)
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